What You Should Know:
– Integral, an innovator in safeguarding privacy and maximizing data quality raises $6.9M in seed funding to protect sensitive health data and provide automated expert certification software that enables health and life sciences companies access to compliant, rich, de-identified data in hours, rather than months.
– The seed round was led by Haystack, The General Partnership, and Virtue Ventures, with additional support from Also Capital, Array Ventures, Caffeinated Capital, GreatPoint Ventures, LiveRamp Ventures, and Venrex.
Real-time Compliance for Life Sciences
Founded in 2022 by Shubh Sinha, CEO and John Kuhn, CTO, Integral streamlines dataset creation by automating the de-identification and compliance certification process. Personal and highly revealing healthcare data such as medical records, health histories, and genetic information, when combined with non-healthcare data such as social media activity, purchasing history, and location data, give researchers a deep, holistic understanding of a person’s health and lifestyle. While this combined data set enhances healthcare research and improves health outcomes, it can pose a significant threat to people’s privacy by potentially exposing sensitive information about individuals. Integral provides higher quality data and expert Certification-as-a-Service software, enabling customers to work with better data in nearly real-time.
“Combining healthcare and non-healthcare data can transform healthcare research and innovation. John and I asked why healthcare companies couldn’t buy and analyze data as quickly as retailers like Target or Walmart, and we’ve made that possible with Integral. We’ve proven and will continue to prove that speed, accuracy, and privacy can be treated equally, even when working with highly regulated data,” said Sinha. “We created Integral to achieve this goal, ensuring personal information is protected and people’s privacy rights are respected. By prioritizing privacy and building trust with the public, researchers can unlock more value from data, which leads to better clinical trials, medications, products, technologies, and more.”
